Regeneron Looks to Avalanche’s Ocular BioFactory™ for Potential Eylea® Successor
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 6 (Table of Contents)
Published: 3 Jun-2014
DOI: 10.3833/pdr.v2014.i6.2036 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In order to strengthen its ophthalmology pipeline and defend its Eylea® (aflibercept) franchise in the long term, Regeneron Pharmaceuticals has partnered with Avalanche Biotechnologies to develop and commercialise next-generation gene therapies for ophthalmologic diseases using Avalanche’s adeno-associated virus (AAV)-based Ocular BioFactory™ platform...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS